News | Ventricular Assist Devices (VAD) | May 29, 2020

Class I Recall Issued for Medtronic HeartWare HVAD Pump

Outflow graft and strain relief recalled due to risk of breaks and tears during set up

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump

May 29, 2020 — Medtronic is recalling its HeartWare HVAD left ventricular assist device (LVAD) pump outflow graft and outflow graft strain relief because it may tear and the strain relief screw may break during assembly prior to implant. Medtronic said the issues might not be observed until during or after the pre-implant pump assembly and attachment to the HVAD pump.

Medtronic has received 92 complaints related to the pre-implant pump assembly process, which includes both the strain relief screw breaking and outflow graft tears. The recall in the U.S. includes 4,924 devices. The recall was initiated April 3, 2020,

The FDA says this is a Class I recall because use of these affected products may cause serious patient harm including dizziness, loss of consciousness, bleeding, fluid buildup around the heart, additional medical procedures or even death.

Read the FDA recall

The recalled medical products include:
   • HVAD Pump Outflow Graft: 1125
   • HVAD Pump Implant Kit: 1103
   • HVAD Implant Accessories Kit: 1153

The HeartWare HVAD Pump Outflow Graft and Outflow Graft Strain Relief, are parts of the HeartWare Ventricular Assist Device (HVAD) System, that help the heart deliver blood to the rest of the body. The HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery, or as destination therapy (DT) in patients where new transplants are not planned.

 

Related Content

Videos | Heart Failure

The University of Maryland Medical Center (UMMC) announced the first successful transplant of a genetically modified pig ...

Home January 11, 2022
Home
Feature | Heart Failure | By Dave Fornell, DAIC Editor

January 10, 2022 — The University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center ...

Home January 10, 2022
Home
News | Heart Failure

December 16, 2021 — MVP Health Care and The University of Vermont Health Network recently announced their joint Medicare ...

Home December 16, 2021
Home
News | Heart Failure

November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...

Home November 19, 2021
Home
News | Heart Failure

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

Home November 17, 2021
Home
News | Heart Failure

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

Home November 10, 2021
Home
News | Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

Home November 02, 2021
Home
News | Heart Failure

October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling ...

Home October 27, 2021
Home
News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
Subscribe Now